Monthly Cost Breakdown: Wegovy vs Mounjaro Pricing
What Is Better Wegovy or Mounjaro: Understanding Monthly Cost Structure
When evaluating what is better Wegovy or Mounjaro for your weight management goals, monthly costs play a decisive role in long-term treatment sustainability. Wegovy follows a structured 16-week dose escalation protocol, with each monthly cost clearly defined from starter through maintenance phases. The monthly investment begins at £79.99 for the 0.25mg starter dose, progressing systematically through £94.99 (0.5mg), £99.99 (1mg), £139.99 (1.7mg), reaching the maintenance dose of £209.99 monthly for 2.4mg. This transparent pricing structure allows patients to budget effectively for their weight management journey.
Mounjaro presents a different cost profile with its tirzepatide formulation, but both medications require similar long-term financial commitment for sustained results. The question of what is better Wegovy or Mounjaro often depends on individual response, tolerability, and importantly, the ability to maintain consistent monthly treatment. EverydayMeds provides both options through our GPhC-registered pharmacy (#9012878), ensuring patients can access either prescription-only medicine with professional clinical oversight.
Wegovy Monthly Pricing: Complete Cost Analysis
Understanding the complete monthly cost structure helps answer what is better Wegovy or Mounjaro from a financial planning perspective. New customers benefit from code FIRST40 applied at checkout, bringing the starter month to £79.99, while returning customers use DOSE25 to maintain competitive pricing throughout treatment. The escalation follows a precise monthly schedule: Month 1 (£79.99), Month 2 (£94.99), Month 3 (£99.99), Month 4 (£139.99), with Month 5 onwards at the maintenance cost of £209.99. This predictable progression eliminates pricing surprises during the critical establishment phase.
Bundle options provide additional convenience for monthly planning, with our Getting Started bundles covering multiple months in single orders. The Intro Duo (0.25mg and 0.5mg) costs £169.99, covering months 1-2, while the Progress Trio (0.5mg, 1mg, and 1.7mg) at £369.99 provides a three-month supply during the crucial middle escalation period. These bundles ensure uninterrupted treatment while simplifying the monthly ordering process through our temperature-controlled delivery system.
Clinical Evidence: Weighing Wegovy vs Mounjaro Effectiveness
When considering what is better Wegovy or Mounjaro, clinical trial data provides essential context for monthly cost justification. In the STEP 1 trial, patients taking Wegovy alongside diet and exercise achieved an average weight loss of approximately 15% at 68 weeks, compared to 2.4% with placebo (Wilding et al., NEJM, 2021). The STEP 5 trial demonstrated sustained weight loss of approximately 15.2% at 2 years, indicating long-term effectiveness that may justify the monthly investment.
Mounjaro's SURMOUNT trials showed different efficacy profiles with its dual GIP and GLP-1 mechanism, though direct comparison between trials is not appropriate due to different study designs and populations. Both medications require ongoing monthly treatment for sustained benefits, as the STEP 1 extension showed patients regained approximately two-thirds of weight lost within one year of stopping treatment. This emphasises that monthly cost considerations should factor in long-term treatment commitment rather than short-term expense.
How Wegovy Works: Monthly Investment in GLP-1 Action
Understanding Wegovy's mechanism helps justify the monthly cost when evaluating what is better Wegovy or Mounjaro for individual needs. Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics natural fullness hormones produced in the intestine. Once-weekly injections work continuously throughout each month, reducing appetite by acting on brain appetite centres and promoting feelings of fullness after smaller meals. The medication may also reduce food cravings, particularly for high-calorie foods, providing ongoing benefit throughout each monthly treatment period. This consistent 24/7 action explains why monthly dosing maintains steady therapeutic levels, unlike daily medications that require multiple purchases. The FlexTouch pen delivery system ensures precise dosing throughout each monthly cycle, maximising the therapeutic benefit from each £79.99-£209.99 monthly investment.
Ordering Process: Streamlined Monthly Supply Management
EverydayMeds simplifies the monthly cost planning for both Wegovy and Mounjaro through our streamlined ordering process, helping patients focus on treatment rather than logistics. The journey begins with a 3-minute online clinical assessment, completed from your smartphone or computer at any time. Our registered prescribers review applications within standard 3 working days, or 24 hours with express service, ensuring timely monthly supply continuation. Once approved, next-day delivery arrives via temperature-controlled cold-chain logistics, maintaining medication integrity throughout transport. Each monthly pen arrives ready for immediate use, with clear instructions for the weekly injection schedule. This reliable monthly delivery cycle means patients can establish predictable treatment routines without supply interruptions, crucial for maintaining the therapeutic benefits that justify the monthly investment.
Storage and Practical Considerations: Monthly Convenience Factors
When determining what is better Wegovy or Mounjaro, practical monthly storage requirements often influence long-term adherence and effective cost management. Wegovy requires refrigeration at 2-8°C before first use but offers significant convenience with 6 weeks room temperature stability once removed from the fridge, compared to Mounjaro's 21-day room temperature limit. This storage advantage means each monthly Wegovy pen provides greater flexibility for travel, work schedules, or lifestyle changes without compromising medication integrity. The FlexTouch pen design delivers precise weekly doses throughout each monthly cycle, with clear dose windows confirming accurate delivery. Each pen contains four weekly doses, perfectly aligned with monthly prescription cycles, and the pre-filled design eliminates preparation time or mixing requirements. This convenience factor reduces the effective time cost of monthly treatment, making the £79.99-£209.99 monthly investment more valuable through improved usability and reduced lifestyle disruption.
What Is Better Wegovy or Mounjaro: Long-term Monthly Budgeting
The question of what is better Wegovy or Mounjaro ultimately depends on individual clinical response, but monthly budgeting considerations help inform sustainable treatment decisions. Wegovy's maintenance dose represents an annual investment of approximately £2,520 (12 × £209.99), providing continuous appetite regulation throughout the year. This annual cost perspective helps patients evaluate the monthly commitment against other weight management approaches, including private specialist consultations, meal replacement programs, or gym memberships that may not provide equivalent clinical outcomes. Planning for the 16-week escalation period requires approximately £614.95 total investment before reaching maintenance dosing, allowing patients to assess treatment response before committing to full maintenance costs.
Monthly cost predictability becomes particularly important given that weight management represents a long-term commitment rather than short-term intervention. The STEP trials demonstrated that sustained benefits require continued treatment, making monthly affordability a crucial factor in treatment success. EverydayMeds' DOSE25 code ensures returning customers maintain competitive monthly pricing throughout extended treatment periods, supporting long-term adherence without price inflation concerns that might compromise treatment continuity.
Expert Guidance: Making Your Monthly Investment Decision
Both Wegovy and Mounjaro are available from EverydayMeds through our GPhC-registered pharmacy (#9012878), and your prescriber can help determine which option provides the best monthly value for your specific circumstances. Our clinical assessment evaluates individual factors including medical history, weight loss goals, lifestyle requirements, and budget considerations to recommend the most appropriate prescription-only medicine. The monthly investment in either medication represents a commitment to clinically-proven weight management support, backed by extensive trial data and regulatory approval for long-term use. New customers can begin their evaluation with code FIRST40 applied at checkout, reducing the initial monthly cost to £79.99 and allowing assessment of individual response before progressing to higher doses. Contact our clinical team through the online assessment to discuss which monthly treatment plan aligns with your weight management goals and financial planning requirements. Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
